Literature DB >> 17923479

Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.

Sai Murali Krishna Pulukuri1, Bharathi Gorantla, Jasti S Rao.   

Abstract

Histone acetylation plays an important role in chromatin remodeling and gene expression. The molecular mechanisms involved in differential regulation of urokinase plasminogen activator (uPA) gene expression are not fully understood. In this study, we investigated whether histone deacetylation was involved in repression of uPA expression in human cancer cells. Induction of uPA expression by histone deacetylase (HDAC) inhibitors trichostatin A (TSA), sodium butyrate, and scriptaid was observed in all three different types of human cancer cells examined. Chromatin immunoprecipitation assays showed that the induction of uPA expression by TSA was accompanied by a remarkable increase of acetylation of histones H3 and H4, which are associated with the uPA promoter region in human cancer cells. These results were further substantiated by the findings of a restriction enzyme accessibility assay and TSA-stimulated uPA promoter activity through the inhibition of HDAC activity. In vitro Matrigel invasion assays showed that induction of uPA expression by HDAC inhibitors in human cancer cells resulted in a significant increase of cancer cell invasion. Furthermore, HDAC1 knockdown by small interference RNA stimulated uPA expression and cancer cell invasion. In conclusion, this study demonstrates the important role of histone modifications in regulating uPA gene expression and raises a possibility that the use of HDAC inhibitors in patients as cancer therapy may paradoxically establish metastasis through up-regulation or reactivation of uPA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923479      PMCID: PMC2156646          DOI: 10.1074/jbc.M705867200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

Review 1.  The plasminogen (fibrinolytic) system.

Authors:  D Collen
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

Review 2.  Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system.

Authors:  F Blasi
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

3.  Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects.

Authors:  L C Sambucetti; D D Fischer; S Zabludoff; P O Kwon; H Chamberlin; N Trogani; H Xu; D Cohen
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

4.  Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo.

Authors:  M Yamamoto; R Sawaya; S Mohanam; A K Bindal; J M Bruner; K Oka; V H Rao; M Tomonaga; G L Nicolson; J S Rao
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

Review 5.  Molecular mechanisms of glioma invasiveness: the role of proteases.

Authors:  Jasti S Rao
Journal:  Nat Rev Cancer       Date:  2003-07       Impact factor: 60.716

6.  Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.

Authors:  Pouya Pakneshan; Rosie Hongmei Xing; Shafaat A Rabbani
Journal:  FASEB J       Date:  2003-06       Impact factor: 5.191

7.  Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion.

Authors:  Li-Teh Liu; Hui-Chiu Chang; Lien-Chai Chiang; Wen-Chun Hung
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

8.  Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.

Authors:  Christopher S Gondi; Sajani S Lakka; Niranjan Yanamandra; Khawar Siddique; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

Review 9.  Epigenetics in human disease and prospects for epigenetic therapy.

Authors:  Gerda Egger; Gangning Liang; Ana Aparicio; Peter A Jones
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

10.  Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3.

Authors:  Xiaohong Zhang; Walker Wharton; Zhigang Yuan; Shih-Chang Tsai; Nancy Olashaw; Edward Seto
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more
  21 in total

1.  Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors.

Authors:  Hui Song; Chia-Wei Li; Adam M Labaff; Seung-Oe Lim; Long-Yuan Li; Shu-Fen Kan; Yue Chen; Kai Zhang; Jingyu Lang; Xiaoming Xie; Yan Wang; Long-Fei Huo; Sheng-Chieh Hsu; Xiaomin Chen; Yingming Zhao; Mien-Chie Hung
Journal:  Biochem Biophys Res Commun       Date:  2010-11-19       Impact factor: 3.575

Review 2.  Histone deacetylases and cancer.

Authors:  Bruna Barneda-Zahonero; Maribel Parra
Journal:  Mol Oncol       Date:  2012-08-27       Impact factor: 6.603

Review 3.  Metal-dependent Deacetylases: Cancer and Epigenetic Regulators.

Authors:  Jeffrey E López; Eric D Sullivan; Carol A Fierke
Journal:  ACS Chem Biol       Date:  2016-03-18       Impact factor: 5.100

4.  Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.

Authors:  Thomas W Hanigan; Shaimaa M Aboukhatwa; Taha Y Taha; Jonna Frasor; Pavel A Petukhov
Journal:  Cell Chem Biol       Date:  2017-09-21       Impact factor: 8.116

Review 5.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

6.  Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer.

Authors:  Kyung Hee Lee; Eun Young Choi; Min Kyoung Kim; Kyeong Ok Kim; Byung Ik Jang; Se Won Kim; Sang Woon Kim; Sun Kyo Song; Jae-Ryong Kim
Journal:  Mol Cell Biochem       Date:  2010-06-18       Impact factor: 3.396

7.  Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease.

Authors:  Nikolai D Belyaev; Natalia N Nalivaeva; Natalia Z Makova; Anthony J Turner
Journal:  EMBO Rep       Date:  2008-12-05       Impact factor: 8.807

8.  Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion.

Authors:  Sophie Iochmann; Claire Bléchet; Valérie Chabot; Annabelle Saulnier; Aniça Amini; Guillaume Gaud; Yves Gruel; Pascale Reverdiau
Journal:  Clin Exp Metastasis       Date:  2009-03-07       Impact factor: 5.150

9.  Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma.

Authors:  Yong Xu; Xiaolin Qin; Jinjing Zhou; Zhiguang Tu; Xiao Bi; Wuxian Li; Xiaoqing Fan; Yi Zhang
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

10.  Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.

Authors:  S M Pulukuri; B Gorantla; J A Knost; J S Rao
Journal:  Oncogene       Date:  2009-06-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.